Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 111-120 of 2785 for cancer

Edit search filters
  1. Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

    Rochester, MN

  2. Combination Chemotherapy in Treating Women With Breast Cancer

  3. A Study to Evaluate the Safety and Effectiveness of AB928-Based Treatment Combinations to Treat Patients with Metastatic Colorectal Cancer

    Scottsdale/Phoenix, AZ

  4. A Study of PROQOL (Patient Reported Outcome Quality of Life) Tool in the Hematology and Oncology Population

    Rochester, MN

  5. Study of Ociperlimab in Combination With Tislelizumab in Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Phase 1/2 Study Of MRTX1719 In Solid Tumors With MTAP Deletion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

    Scottsdale/Phoenix, AZ

  8. Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

    Rochester, MN

  9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

  10. A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Jacksonville, FL

.

Mayo Clinic Footer